Lidman: It is expected that the net profit will be a loss of 15 to 28 million yuan in 2025.

Lidman's announcement predicts a net loss of 15-28 million yuan in 2025, compared to a loss of 75.10 million yuan in the same period last year. The estimated impact of non-recurring gains and losses on net profit for the current period is approximately 9 million yuan, compared to 22.37 million yuan in the same period last year. During the reporting period, the company's main business revenue and gross profit margin of diagnostic reagents products decreased year-on-year due to factors such as the expansion of domestic diagnostic reagents procurement varieties, further implementation of DRG/DIP policies, and intensified industry competition, resulting in a loss for the net profit attributable to shareholders of the listed company.